Healthcare Industry News: Mitral Contour System
News Release - April 20, 2006
Steven Goldberg, M.D. Joins Cardiac Dimensions as Chief Clinical OfficerKIRKLAND, Wash.--(HSMN NewsFeed)--April 20, 2006--Cardiac Dimensions® Inc. today announced that Steven Goldberg, M.D., Director of the Cardiac Catheterization Lab at University of Washington Medical Center, has joined the company as Chief Clinical Officer. Dr. Goldberg will work closely with Cardiac Dimensions Chief Medical Officer, David Reuter, M.D., PhD., in supporting the company's ongoing worldwide clinical trials of the CARILLON(TM) Mitral Contour System(TM).
Dr. Goldberg is a board certified interventional cardiologist. After completing his fellowship at U.C. Irvine working with Dr. Jonathan Tobis, he served as Associate Director of the Catheterization Lab and Assistant Professor of Medicine at Harbor-UCLA. Prior to joining University of Washington Medical Center, he was Director of the Catheterization Lab at West LA, VA Medical Center. In addition to his new responsibilities at Cardiac Dimensions, he will maintain his current clinical, educational, administrative, and research duties at the University of Washington Medical Center.
"We are very excited to have him on board and I know Steve looks forward to working with our clinical investigators to help bring our important therapy through successful clinical trials," commented Rick Stewart, President and CEO of Cardiac Dimensions.
Approximately 5 million people in the U.S. and over 20 million people worldwide suffer from Heart Failure. The majority of those suffer from dilated cardiomyopathy and functional mitral regurgitation (FMR). While surgical options exist and can be effective in reducing FMR, they are infrequently used due to the burden of the surgery itself, which is associated with high operative morbidity and mortality rates.
The CARILLON Mitral Contour System is an investigational device that combines a proprietary implantable device and delivery system. The implant consists of a shaping ribbon between distal and proximal anchors, and is delivered percutaneously (through the skin) via jugular access under fluoroscopic guidance. The implant is designed to be positioned, adjusted, and gently anchored in the coronary sinus/great cardiac vein (GCV) to reshape the annulus around the mitral valve to reduce mitral regurgitation (MR). Preclinical data has demonstrated both a reduction in MR and an improvement in Cardiac Output. Clinical studies are ongoing in both the U.S. and Europe.
Cardiac Dimensions Inc. is based in Kirkland, WA, and develops and manufactures devices designed for treating heart failure and related conditions. It is a privately held company whose investors include MPM Capital, Interwest Partners, Polaris, and Frazier Health Care.
For further information contact Tom Douthitt at 425 605-5900 or visit our Web site at www.cardiacdimensions.com.
Source: Cardiac Dimensions
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsCardiac Dimensions Announces $17.5 Million Series C Financing to Accelerate Sales Expansion of The Carillon Mitral Contour System(R)
Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral Regurgitation